Treace Medical Concepts, Inc.
TMCIHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Treace Medical Concepts, Inc. (TMCI) is listed under Medical Devices. At a $277.7M market cap, Treace Medical Concepts, Inc. ranks as a micro-cap company within healthcare. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Market Cap
$277.7M
Beta
1.49
P/E (TTM)
—
P/E (Fwd)
-5.02
EPS (TTM)
$-0.92
EPS (Fwd)
$-0.85
ROE
-72.0%
ROA
-17.3%
Cash
$45.6M
Total Debt
$73.0M
Free CF
-$6.3M
52W Change
-37.9%
Annual Financials
Cash vs Debt
Where TMCI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TMCI finished 10.86% above its 150-day moving average ($3.50) and 22.78% above its 200-day moving average ($3.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TMCI overbought or oversold?
At the October 20, 2026 close, TMCI's RSI(14) was 27.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, TMCI has $45.6M in cash with $73.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$6.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -72.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $141.8M (2022) to $212.7M (2025), reflecting a 50% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TMCI.